SEC Tracker
Get the app
NTLA · XBRL financial data

Intellia Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (NTLA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Apr 30, 2026Jun 30, 2026
Revenue from contracts with customers12(2)*297913*17141423*—8
Research and development114109*112114123117*108979589*—83
General and administrative2929*31323132*29273133*—38
Operating income (loss)(131)(140)*(114)(139)(145)(136)*(121)(110)(111)(99)*—(113)
Interest income1312*13121211*9776*—6
Other income (expense)98*7(8)98*69103*—6
Income tax expense (benefit)—————————year only——
Net income (loss)(122)(132)*(107)(147)(136)(129)*(114)(101)(101)(96)*—(107)
Earnings per share, basic USD per share(1.38)(1.46)*(1.12)(1.52)(1.34)(1.27)*(1.10)(0.98)(0.92)(0.83)*—(0.80)
Earnings per share, diluted USD per share(1.38)(1.46)*(1.12)(1.52)(1.34)(1.27)*(1.10)(0.98)(0.92)(0.83)*—(0.80)
Weighted average shares, basic millions of shares8990*9697101102*104104110116*—133
Weighted average shares, diluted millions of shares8990*9697101102*104104110116*—133

Balance sheet

CSV

Fiscal quarters (NTLA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Apr 30, 2026Jun 30, 2026
Cash and cash equivalents168227172131120189127156193155—106
Marketable securities687685619560538412377303318294—332
Marketable securities, non-current138100162249287260203171159155—191
Accounts receivable6363612991111119—7
Prepaid and other current assets32505654443037256068—83
Total current assets893998884757711640551496582528—528
Property and equipment, net34333230292725232018—15
Right-of-use asset119115110105100219138129118106—86
Total assets1,2431,3011,2601,1921,1731,191986899925842—857
Accounts payable471419131512101320—12
Accrued liabilities58674345515541424150—44
Total current liabilities92115981051061111139594104—79
Lease liability, non-current1019792878219080767167250
Total liabilities206251223220211319206184177171—129
Accumulated deficit(1,526)(1,658)(1,766)(1,913)(2,049)(2,177)(2,292)(2,393)(2,494)(2,590)—(2,793)
Total stockholders' equity1,0371,0501,036971963872780715748671—728
Total liabilities and equity1,2431,3011,2601,1921,1731,191986899925842—857
Common shares outstanding (cover page) millions of shares909696102102104104107116118140140

Cash flows

CSV

Fiscal quarters (NTLA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Apr 30, 2026Jun 30, 2026
Net income (loss)(122)(132)*(107)(147)(136)(129)*(114)(101)(101)(96)*—(107)
Stock-based compensation35*35*3441*40*40*2222*20*17*—18*
Depreciation and amortization2*2*3333*2322*—2
Net cash from operating activities(101)*(93)*(121)(58)*(85)*(85)*(149)(100)*(77)*(69)*—(83)*
Purchases of property and equipment4*2*31*1*1*10*0*0*—2*
Net cash from investing activities80*46*6(24)*(8)*152*94107*(1)*28*—(142)*
Proceeds from issuing common stock—year only———year only———year only——
Net cash from financing activities19*106*6041*82*2*015*115*2*—196*
Net change in cash(3)*59*(55)(41)*(10)*69*(55)22*37*(40)*—(29)*

Compare with peers

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Intellia Therapeutics1067.7(83)*140.1M5.3 quarters 10-QJun 30, 2026
Geron6357(16)*642.5M4.0 quarters 10-QJun 30, 2026
Wave Life Sciences19713(60)*197.2M7.4 quarters 10-QSep 30, 2026
CorMedix25710286*77.9M— 10-QJun 30, 2026
Ardelyx461282.2*251.4M— 10-QSep 30, 2026
Collegium Pharmaceutical12920071*32.6M— 10-QJun 30, 2026
Niagen Bioscience67302.8*79.1M— 10-QJun 30, 2026
Nurix Therapeutics720673616*109.2M— 10-QAug 31, 2026
Viridian Therapeutics17326(93)*113.6M9.0 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.